Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • MHRA

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    MHRA marks 100 years of patient safety through biological standards

    The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

    - PMLiVE

    MHRA and FDA expand collaboration on AI and medtech regulation

    National Commission on the Regulation of AI in Healthcare brings together UK and US experts

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    Ipsen’s tumour treatment receives MHRA marketing authorisation

    This is the first approval in the UK for previously treated advanced neuroendocrine tumours

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    - PMLiVE

    UK’s first new type of antibiotic for UTIs in nearly 30 years approved by MHRA

    The oral pill is effective against many drug-resistant infections, including E. coli

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links